Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs have been gaining popularity in Eastern Europe due to the increasing prevalence of respiratory diseases. The market for these drugs has been growing steadily in the region, with several factors contributing to its development.
Customer preferences: Customers in Eastern Europe are increasingly becoming aware of the benefits of bronchodilator drugs in managing respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Patients are looking for drugs that provide quick relief from symptoms such as shortness of breath and wheezing, and bronchodilator drugs have been effective in providing such relief. Additionally, the convenience of using inhalers as a mode of drug delivery is also driving the demand for these drugs.
Trends in the market: One of the major trends in the bronchodilator drugs market in Eastern Europe is the increasing use of combination therapies. Combination therapies involve the use of two or more bronchodilator drugs in a single inhaler device, providing better symptom relief and improving patient adherence to treatment. Another trend is the increasing use of long-acting bronchodilators, which provide sustained relief from symptoms for up to 24 hours.
Local special circumstances: Eastern Europe has a high prevalence of respiratory diseases, which is driving the demand for bronchodilator drugs. Additionally, the region has a high smoking rate, which is a major risk factor for respiratory diseases. This has led to an increased need for effective treatment options, such as bronchodilator drugs.
Underlying macroeconomic factors: The healthcare sector in Eastern Europe is undergoing significant reforms, with an increasing focus on providing universal healthcare coverage. This has led to an increase in healthcare spending, which is driving the growth of the bronchodilator drugs market. Additionally, the region has a growing elderly population, which is more susceptible to respiratory diseases, further driving the demand for these drugs. The increasing availability of generic drugs is also contributing to the growth of the market, as it is making these drugs more affordable and accessible to a larger population.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
